EI
CLDX icon

EAM Investors’s Celldex Therapeutics CLDX Stock Holding History

EAM Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,115
Closed -$2.94M – 267
2024
Q1 		$2.94M Buy
+70,115
New +$2.88M 0.46% 122
2023
Q2 		– Sell
-46,216
Closed -$1.66M – 285
2023
Q1 		$1.66M Sell
46,216
-9,996
-18% -$431K 0.33% 148
2022
Q4 		$2.51M Buy
+56,212
New +$2.01M 0.52% 59
2021
Q4 		– Sell
-86,399
Closed -$4.67M – 295
2021
Q3 		$4.67M Buy
86,399
+35,866
+71% +$1.68M 0.79% 7
2021
Q2 		$1.69M Buy
+50,533
New +$1.39M 0.26% 175
2021
Q1 		– Sell
-100,259
Closed -$1.76M – 354
2020
Q4 		$1.76M Sell
100,259
-40,870
-29% -$736K 0.29% 162
2020
Q3 		$2.09M Buy
141,129
+72,003
+104% +$843K 0.5% 56
2020
Q2 		$899K Buy
+69,126
New +$306K 0.2% 203
2015
Q1 		– Sell
-7,505
Closed -$2.06M – 339
2014
Q4 		$2.06M Buy
+7,505
New +$1.87M 0.29% 161
2014
Q1 		– Sell
-3,776
Closed -$1.37M – 320
2013
Q4 		$1.37M Sell
3,776
-1,523
-29% -$587K 0.25% 192
2013
Q3 		$2.82M Sell
5,299
-9,442
-64% -$3.24M 0.56% 29
2013
Q2 		$3.45M Buy
+14,741
New +$2.9M 0.75% 11

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's CLDX Position: Q2 2024 in Review

EAM Investors sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 70,115 shares — an estimated $2.94M sold.

EAM Investors first reported a position in CLDX in Q2 2013 and held it in 12 quarters. The position peaked at $4.67M in Q3 2021. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • EAM Investors reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EAM Investors sold 70,115 Celldex Therapeutics shares in Q2 2024, an estimated $2.94M.
  • EAM Investors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 12 quarters.
  • EAM Investors's Celldex Therapeutics position peaked at $4.67M in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.